ArticleFrontiers in aging neuroscience2026
MultimodalCNN-PD: a Parkinson's disease diagnostics framework using multimodal convolutional neural network.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AGMNet: an explainable gated multimodal framework integrating MRI heterogeneity and dopaminergic asymmetry for Parkinson's disease classification.Frontiers in artificial intelligence · 2026Article
- A game-theoretic framework for multimodal information utilization under heterogeneous processing environments in neuroscience and perception science.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a prevalent neurodegenerative disorder that severely affects motor and cognitive functions. Early diagnosis, particularly during the prodromal phase, is critical for effective intervention. Methods: This study presents MultimodalCNN-PD++, a deep learning model that integrates Magnetic Resonance Imaging (MRI) with clinical metadata (including motor/cognitive assessments, demographic data, and genetic biomarkers) to enhance PD classification. The model employs a lightweight EfficientNetB0 backbone, Mobile Convolutional Block Attention Modules (Mobile CBAM), and an enhanced Meta-Guided Cross-Attention (MGCA++) mechanism. A three-stage hierarchical feature selection method identifies the most discriminative clinical features, while metadata is processed with BioClinicalBERT using Low-Rank Adaptation (LoRA). Results: Validated on the Parkinson's Progression Markers Initiative (PPMI) dataset, the model achieved 97.5% accuracy in distinguishing Normal Control, prodromal PD, and diagnosed PD cases, with reduced parameters and computational costs. External validation on the OASIS-3 dataset confirmed robust generalizability (96.2% accuracy) despite demographic and acquisition protocol variations. Ablation studies highlighted the contributions of Mobile CBAM, MGCA++, hierarchical feature selection, and BioClinicalBERT-LoRA. Discussion: This framework sets a new benchmark for multiclass PD diagnosis, demonstrating strong potential as a clinically deployable AI tool for early detection and personalized management of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.